Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
2436- MET,    Metformin alleviates nickel-induced autophagy and apoptosis via inhibition of hexokinase-2, activating lipocalin-2, in human bronchial epithelial cells
- in-vitro, Nor, BEAS-2B
*HK2↓,
2492- MET,    The Metformin Mechanism on Gluconeogenesis and AMPK Activation: The Metabolite Perspective
- Review, Nor, NA
*glucose↓, *glucoNG↓, *AMPK↑,
2491- MET,    Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
- in-vivo, Nor, NA
*glucoNG↓, *glucose↓, *mitResp↓,
2376- MET,    Metformin Inhibits Epithelial-to-Mesenchymal Transition of Keloid Fibroblasts via the HIF-1α/PKM2 Signaling Pathway
- in-vitro, Nor, NA
*Hif1a↓, *EMT↓, *p‑P70S6K↓, *PKM2↓,
2375- MET,    Metformin inhibits gastric cancer via the inhibition of HIF1α/PKM2 signaling
- in-vitro, GC, SGC-7901
tumCV↓, TumCI↓, TumCMig↓, Apoptosis↑, PARP↓, PI3K↓, Akt↓, Hif1a↓, PKM2↓, COX2/PTGS2↓,
2371- MET,    The role of pyruvate kinase M2 in anticancer therapeutic treatments
- Review, Var, NA
ChemoSen↑, PKM2↓, Hif1a↓, EMT↓,
2377- MET,    Metformin Inhibits TGF-β1-Induced Epithelial-to-Mesenchymal Transition via PKM2 Relative-mTOR/p70s6k Signaling Pathway in Cervical Carcinoma Cells
- in-vitro, Cerv, HeLa - in-vitro, Cerv, SiHa
EMT↓, P70S6K↓, mTOR↓, PKM2↓, Warburg↓, AMPK↑,
2378- MET,    Metformin inhibits epithelial-mesenchymal transition of oral squamous cell carcinoma via the mTOR/HIF-1α/PKM2/STAT3 pathway
- in-vitro, SCC, CAL27 - in-vivo, NA, NA
TumCP↓, TumCMig↓, TumCI↓, EMT↓, mTOR↓, Hif1a↓, PKM2↓, STAT3↓, E-cadherin↑, Vim↓, Snail↓, STAT3↓,
2379- MET,    Down‐regulation of PKM2 enhances anticancer efficiency of THP on bladder cancer
- in-vitro, Bladder, T24/HTB-9 - in-vitro, BC, UMUC3
PKM2↓, p‑STAT3↓, TumCG↓, eff↑, chemoP↑, AMPK↑,
2383- MET,    Activation of AMPK by metformin promotes renal cancer cell proliferation under glucose deprivation through its interaction with PKM2
- in-vitro, RCC, A498
AMPK↑, TumCP↓, eff↓, eff↑,
2374- MET,    Metformin Induces Apoptosis and Downregulates Pyruvate Kinase M2 in Breast Cancer Cells Only When Grown in Nutrient-Poor Conditions
- in-vitro, BC, MCF7 - in-vitro, BC, SkBr3 - in-vitro, BC, MDA-MB-231
eff↑, Apoptosis↑, Glycolysis↓, PKM2↓, mTOR↓, PARP↓,
2384- MET,    Integration of metabolomics and transcriptomics reveals metformin suppresses thyroid cancer progression via inhibiting glycolysis and restraining DNA replication
- in-vitro, Thyroid, BCPAP - in-vivo, NA, NA - in-vitro, Thyroid, TPC-1
Glycolysis↓, OXPHOS↑, tumCV↓, TumCI↓, TumCMig↓, EMT↓, Apoptosis↑, TumCCA↑, LDHA↓, PKM2↓, IDH1↑, TumCG↓,
2385- MET,    Metformin activates chaperone-mediated autophagy and improves disease pathologies in an Alzheimer disease mouse model
- in-vitro, AD, H4 - in-vitro, NA, HEK293 - in-vivo, NA, NA - in-vitro, NA, SH-SY5Y
*HK2↓, *PKM2↓, *Dose↝, IKKα↑, memory↑, p‑Hsc70↑, APP↓,
2386- MET,    Mechanisms of metformin inhibiting cancer invasion and migration
- Review, Var, NA
OS↑, AMPK↑, EMT↓, TGF-β↓, mTOR↓, P70S6K↓, PKM2↓, Hif1a↓, ChemoSen↑,
2387- MET,  GEM,    Metformin Increases the Response of Cholangiocarcinoma Cells to Gemcitabine by Suppressing Pyruvate Kinase M2 to Activate Mitochondrial Apoptosis
- in-vitro, CCA, HCC9810
eff↑, tumCV↓, TumCMig↓, TumCI↓, Apoptosis↑, PKM2↓, PDHB↓,
2487- metroC,    Metronomic Chemotherapy: Possible Clinical Application in Advanced Hepatocellular Carcinoma
- Review, HCC, NA
toxicity↓, toxicity↓, eff↝, angioG↓, CSCs↓, TSP-1↑, Hif1a↓, VEGF↓, eff↑,
2490- metroC,    Durable complete response of hepatocellular carcinoma after metronomic capecitabine
- Case Report, HCC, NA
angioG↓, TumVol↓, Remission↑,
2489- metroC,  capec,    Long-lasting response with metronomic capecitabine in advanced hepatocellular carcinoma
- Case Report, HCC, NA
Dose↝, OS↑, TumVol↓, AFP↓,
2488- metroC,    Metronomic S-1 Chemotherapy and Vandetanib: An Efficacious and Nontoxic Treatment for Hepatocellular Carcinoma
- in-vitro, HCC, HUH7 - in-vivo, HCC, NA
TumCG↓, toxicity↓, OS↑, TSP-1↑, Dose↓, Dose↓,
2486- metroC,  capec,    Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases
- Case Report, HCC, NA
OS↑, eff↝, Dose↝, AFP↓, Dose↝, TumVol↓, AFP↓,
2250- MF,  MNPs,    Confronting stem cells with surface-modified magnetic nanoparticles and low-frequency pulsed electromagnetic field
- Review, NA, NA
*Ca+2↑, *Dose↝, *BioAv↓,
2252- MF,  HPT,    Cellular Response to ELF-MF and Heat: Evidence for a Common Involvement of Heat Shock Proteins?
- Review, NA, NA
HSPs∅, *HSPs↑, eff↝, *eff↑, eff↑, eff↓,
2251- MF,  Rad,    BEMER Electromagnetic Field Therapy Reduces Cancer Cell Radioresistance by Enhanced ROS Formation and Induced DNA Damage
- in-vitro, Lung, A549 - in-vitro, HNSCC, UTSCC15 - in-vitro, CRC, DLD1 - in-vitro, PC, MIA PaCa-2
RadioS↑, DNAdam↑, ROS↑, ChemoSen∅, Pyruv↓, ADP:ATP↓, ROS↑,
2242- MF,    Electromagnetic stimulation increases mitochondrial function in osteogenic cells and promotes bone fracture repair
- in-vitro, Nor, NA
*MMP↑, *Diff↑, *OXPHOS↑, *BMD↑, ATP∅,
2249- MF,    Pulsed electromagnetic fields modulate energy metabolism during wound healing process: an in vitro model study
- in-vitro, Nor, L929
*TumCMig↑, *tumCV↑, *Glycolysis↑, *ROS↓, *mitResp↓, *other↝, *OXPHOS↓, *pH↑, *antiOx↑, *PFKM↑, *PFKL↑, *PKM2↑, *HK2↑, *GLUT1↑, *GPx1↑, *GPx4↑, *SOD1↑,
2248- MF,    Magnetic fields modulate metabolism and gut microbiome in correlation with Pgc-1α expression: Follow-up to an in vitro magnetic mitohormetic study
- in-vivo, Nor, NA
*PGC-1α↑, *GutMicro↑, *FAO↓, *Insulin↓,
2241- MF,    Pulsed electromagnetic therapy in cancer treatment: Progress and outlook
- Review, Var, NA
other↝, p‑ERK↝, P53↝, Cyt‑c↝, OXPHOS↑, Apoptosis↑, ROS↑,
2247- MF,    Effects of Pulsed Electromagnetic Field Treatment on Skeletal Muscle Tissue Recovery in a Rat Model of Collagenase-Induced Tendinopathy: Results from a Proteome Analysis
- in-vivo, Nor, NA
*Glycolysis↓, *LDHB↑, *NAD↑, *ATP↑, *antiOx↑, *ROS↑, *YAP/TEAD↑, *PGC-1α↑, *TCA↑, *FAO↑, *OXPHOS↑,
2246- MF,    The Use of Pulsed Electromagnetic Field to Modulate Inflammation and Improve Tissue Regeneration: A Review
- in-vitro, Nor, NA
*Inflam↓, *IL1↓, *IL6↓, IL17↓, *TNF-α↓,
2245- MF,    Quantum based effects of therapeutic nuclear magnetic resonance persistently reduce glycolysis
- in-vitro, Nor, NIH-3T3
Warburg↓, Hif1a↓, *Hif1a∅, Glycolysis↓, *lactateProd↓, *ADP:ATP↓, Pyruv↓, ADP:ATP↓, *PPP↓, *mt-ROS↑, *ROS↓, RPM↑, *ECAR↓,
2244- MF,    Little strokes fell big oaks: The use of weak magnetic fields and reactive oxygen species to fight cancer
- Review, Var, NA
RPM↑, Glycolysis∅, ROS↑, ChemoSen↑, RadioS↑, selectivity↑,
2243- MF,    Pulsed electromagnetic fields increase osteogenetic commitment of MSCs via the mTOR pathway in TNF-α mediated inflammatory conditions: an in-vitro study
- in-vitro, Nor, NA
*eff↑, *mTOR↑, *Akt↑, *PKA↑, *MAPK↑, *ERK↑, *BMP2↑, *Diff↑, *PKCδ↓, *VEGF↑, *IL10↑,
2254- MF,    Effect of 60 Hz electromagnetic fields on the activity of hsp70 promoter: an in vivo study
- in-vivo, Nor, NA
*HSP70/HSPA5↑, HSP70/HSPA5↑,
2235- MF,    Increase of intracellular Ca2+ concentration in Listeria monocytogenes under pulsed magnetic field
- in-vitro, Inf, NA
Ca+2↑, TumCD↑,
2236- MF,    Changes in Ca2+ release in human red blood cells under pulsed magnetic field
- in-vitro, Nor, NA
*Ca+2↓, *eff↓, *ROS↓,
2237- MF,    The Effect of Pulsed Electromagnetic Field Stimulation of Live Cells on Intracellular Ca2+ Dynamics Changes Notably Involving Ion Channels
- in-vitro, AML, KG-1 - in-vitro, Nor, HUVECs
Ca+2↑, selectivity↑, *Inflam↓, *TNF-α↓, *NF-kB↓, *Ca+2↓,
2238- MF,    Electromagnetic fields act via activation of voltage-gated calcium channels to produce beneficial or adverse effects
- Review, Var, NA
*BMD↑, *VGCC↑, *Ca+2↑, *NO↑, *eff↓,
2239- MF,    Time-varying magnetic fields increase cytosolic free Ca2+ in HL-60 cells
- in-vitro, AML, HL-60
Ca+2↑, eff↝,
2240- MF,    Pulsed electromagnetic field induces Ca2+-dependent osteoblastogenesis in C3H10T1/2 mesenchymal cells through the Wnt-Ca2+/Wnt-β-catenin signaling pathway
- in-vitro, Nor, C3H10T1/2
*Ca+2↑, *Diff↑, *BMD↑, *Wnt↑, *β-catenin/ZEB1↑, *eff↝,
2261- MF,    Tumor-specific inhibition with magnetic field
- in-vitro, Nor, GP-293 - in-vitro, Liver, HepG2 - in-vitro, Lung, A549
ROS↑, Ca+2↓, Apoptosis↑, *selectivity↑, TumCG↓, *i-Ca+2↓, i-Ca+2↑,
2260- MF,    Alternative magnetic field exposure suppresses tumor growth via metabolic reprogramming
- in-vitro, GBM, U87MG - in-vitro, GBM, LN229 - in-vivo, NA, NA
TumCP↓, TumCG↓, OS↑, ROS↑, SOD2↑, eff↓, ECAR↓, OCR↑, selectivity↑, *toxicity∅, TumVol↓, PGC-1α↑, OXPHOS↑, Glycolysis↓, PKM2↓,
2257- MF,  HPT,    HSP70 Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer
- in-vitro, Ovarian, NA
eff↑, eff↑,
2256- MF,  HPT,    Effects of exposure to repetitive pulsed magnetic stimulation on cell proliferation and expression of heat shock protein 70 in normal and malignant cells
- in-vitro, BC, MCF7 - in-vitro, Cerv, HeLa - in-vitro, Nor, HBL-100
HSP70/HSPA5↑, HSP70/HSPA5∅,
2255- MF,    Pulsed Electromagnetic Fields Induce Skeletal Muscle Cell Repair by Sustaining the Expression of Proteins Involved in the Response to Cellular Damage and Oxidative Stress
- in-vitro, Nor, SkMC
*HSP70/HSPA5↑, *Apoptosis↓, *Inflam↓, *Trx↓, *PONs↓, *SOD2↓, *TumCG↑, *Diff↑, *HIF2a↑, *Cyt‑c↑, P21↑,
2253- MF,    Low-frequency pulsed electromagnetic field promotes functional recovery, reduces inflammation and oxidative stress, and enhances HSP70 expression following spinal cord injury
- in-vivo, Nor, NA
*Inflam↓, *TNF-α↓, *IL1β↓, *NF-kB↓, *iNOS↓, *ROS↓, Catalase↑, *SOD↑, *HSP70/HSPA5↑, *neuroP↑, *motorD↑, *antiOx↑,
6939- MF,    A prospective, randomized, placebo controlled, double-blind study of pelvic electromagnetic therapy for the treatment of chronic pelvic pain syndrome with 1 year of followup
- Trial, Nor, NA
*Pain↓,
6938- MF,    Effect of pulsed electromagnetic field therapy on prostate volume and vascularity in the treatment of benign prostatic hyperplasia: a pilot study in a canine model
- in-vivo, BPH, NA
*Dose↝, *toxicity↓, *BloodF↑, *Dose↝, *PV↓, *Inflam↓,
6937- MF,    Noninvasive treatment for men suffering from enlarged prostate
- Review, BPH, NA
*PV↓, *Inflam↓, *BloodF↑, *Dose↝,
6936- MF,  Ex,    Pulsed electromagnetic field with or without exercise therapy in the treatment of benign prostatic hyperplasia
- Trial, BPH, NA
*eff↑, *eff↑, *BloodF↑, *Diff↝, *Dose↝, *Dose↝, *Dose↝, *Dose↝, *Dose↝, *Dose↝, *Dose↝, *UFR↑, *UR↓, *PSA↓, *other↑, *Inflam↓,
6942- MF,    Emerging techniques in ‘truly’ minimal-invasive treatment options of benign prostatic obstruction
- Review, BPH, NA
PV↓,

Showing Research Papers: 5751 to 5800 of 8269
Prev Page 116 of 166 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8269

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

PV↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↑, 1,   OXPHOS↑, 3,   ROS↑, 6,   RPM↑, 2,   SOD2↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ADP:ATP↓, 2,   ATP∅, 1,   OCR↑, 1,   PGC-1α↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 4,   ECAR↓, 1,   Glycolysis↓, 4,   Glycolysis∅, 1,   IDH1↑, 1,   LDHA↓, 1,   PDHB↓, 1,   PKM2↓, 10,   Pyruv↓, 2,   Warburg↓, 2,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   Apoptosis↑, 6,   Cyt‑c↝, 1,   TumCD↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,   tumCV↓, 3,  

Protein Folding & ER Stress(tgid=8) ⓘ

p‑Hsc70↑, 1,   HSP70/HSPA5↑, 2,   HSP70/HSPA5∅, 1,   HSPs∅, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   P53↝, 1,   PARP↓, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

P21↑, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CSCs↓, 1,   EMT↓, 5,   p‑ERK↝, 1,   mTOR↓, 4,   P70S6K↓, 2,   PI3K↓, 1,   STAT3↓, 2,   p‑STAT3↓, 1,   TumCG↓, 5,  

Migration(tgid=13) ⓘ

APP↓, 1,   Ca+2↓, 1,   Ca+2↑, 3,   i-Ca+2↑, 1,   E-cadherin↑, 1,   Snail↓, 1,   TGF-β↓, 1,   TSP-1↑, 2,   TumCI↓, 4,   TumCMig↓, 4,   TumCP↓, 3,   Vim↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 2,   Hif1a↓, 6,   VEGF↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   IKKα↑, 1,   IL17↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 3,   ChemoSen∅, 1,   Dose↓, 2,   Dose↝, 3,   eff↓, 3,   eff↑, 8,   eff↝, 4,   RadioS↑, 2,   selectivity↑, 3,  

Clinical Biomarkers(tgid=22) ⓘ

AFP↓, 3,  

Functional Outcomes(tgid=23) ⓘ

chemoP↑, 1,   memory↑, 1,   OS↑, 5,   Remission↑, 1,   toxicity↓, 3,   TumVol↓, 4,  
Total Targets: 78

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

PV↓, 2,   UFR↑, 1,   UR↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 3,   GPx1↑, 1,   GPx4↑, 1,   OXPHOS↓, 1,   OXPHOS↑, 2,   ROS↓, 4,   ROS↑, 1,   mt-ROS↑, 1,   SOD↑, 1,   SOD1↑, 1,   SOD2↓, 1,   Trx↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ADP:ATP↓, 1,   ATP↑, 1,   Insulin↓, 1,   mitResp↓, 2,   MMP↑, 1,   PGC-1α↑, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 1,   ECAR↓, 1,   FAO↓, 1,   FAO↑, 1,   glucoNG↓, 2,   glucose↓, 2,   Glycolysis↓, 1,   Glycolysis↑, 1,   HK2↓, 2,   HK2↑, 1,   lactateProd↓, 1,   LDHB↑, 1,   NAD↑, 1,   PFKL↑, 1,   PFKM↑, 1,   PKM2↓, 2,   PKM2↑, 1,   PONs↓, 1,   PPP↓, 1,   TCA↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↑, 1,   Apoptosis↓, 1,   BMP2↑, 1,   Cyt‑c↑, 1,   iNOS↓, 1,   MAPK↑, 1,   YAP/TEAD↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↑, 1,   other↝, 1,   tumCV↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

HSP70/HSPA5↑, 3,   HSPs↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Diff↑, 4,   Diff↝, 1,   EMT↓, 1,   ERK↑, 1,   mTOR↑, 1,   p‑P70S6K↓, 1,   TumCG↑, 1,   VGCC↑, 1,   Wnt↑, 1,  

Migration(tgid=13) ⓘ

Ca+2↓, 2,   Ca+2↑, 3,   i-Ca+2↓, 1,   PKA↑, 1,   PKCδ↓, 1,   TumCMig↑, 1,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

Hif1a↓, 1,   Hif1a∅, 1,   HIF2a↑, 1,   NO↑, 1,   VEGF↑, 1,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL1↓, 1,   IL10↑, 1,   IL1β↓, 1,   IL6↓, 1,   Inflam↓, 7,   NF-kB↓, 2,   PSA↓, 1,   TNF-α↓, 3,  

Cellular Microenvironment(tgid=17) ⓘ

pH↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   Dose↝, 12,   eff↓, 2,   eff↑, 4,   eff↝, 1,   selectivity↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

BloodF↑, 3,   BMD↑, 3,   GutMicro↑, 1,   IL6↓, 1,   PSA↓, 1,  

Functional Outcomes(tgid=23) ⓘ

motorD↑, 1,   neuroP↑, 1,   Pain↓, 1,   toxicity↓, 1,   toxicity∅, 1,  
Total Targets: 100

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page